{
    "title": "109_hr3568",
    "content": "The Act titled \"Angie Fatino Save Our Children from Meth Act of 2005\" amends the Controlled Substances Act to transfer ephedrine, pseudoephedrine, and phenylpropanolamine to Schedule V. The Attorney General will transfer ephedrine, pseudoephedrine, and phenylpropanolamine to Schedule V of controlled substances within 90 days of the Angie Fatino Save Our Children from Meth Act of 2005. Pseudoephedrine in certain products will continue to be regulated as a List I chemical. The Angie Fatino Save Our Children from Meth Act of 2005 transfers ephedrine, pseudoephedrine, and phenylpropanolamine to Schedule V of controlled substances. Pseudoephedrine in specific products remains regulated as a List I chemical, including those with no more than 360 milligrams in liquid form approved under section 505 of the Federal Food, Drug, and Cosmetic Act. Pseudoephedrine in such products is considered a list I chemical. The term 'pseudoephedrine' includes salts, optical isomers, and salts of optical isomers. A 'schedule V pseudoephedrine product' contains pseudoephedrine but is not a list I pseudoephedrine product. The term 'list I pseudoephedrine product' refers to a product containing pseudoephedrine approved under section 505 of the Federal Food, Drug, and Cosmetic Act. Regulation of pseudoephedrine as List I chemical; exceptions from definition of regulated transaction; conforming amendments regarding Schedule V products. Amendment to the Controlled Substances Act regarding transactions involving listed chemicals in drugs marketed lawfully in the US, with conditions to prevent diversion for illicit production of controlled substances. Amendment to the Controlled Substances Act involves setting thresholds for transactions involving listed chemicals in drugs to prevent diversion for illicit production of controlled substances. This includes restrictions on transactions of list I pseudoephedrine products unless approved by the Attorney General. Additionally, there are amendments to paragraph numbers for retail distributors. SEC. 4. RESTRICTIONS ON NONPRESCRIPTION RETAIL SALES OF PSEUDOEPHEDRINE. Section 303 of the Controlled Substances Act is amended to include conditions for the sale of list I pseudoephedrine products at retail, such as placing products behind the counter and not selling packages that can be further divided. The Controlled Substances Act is amended to include conditions for the sale of list I pseudoephedrine products at retail, including selling products behind the counter, limiting sales to one product per individual in a 24-hour period, maintaining a logbook of sales, and verifying the age and identity of purchasers. The registrant must maintain a logbook of sales, verifying purchaser's identity and age, keeping the logbook for at least 12 months after the last sale, and not offering free products with purchases. A notice must be posted on the premises stating the federal law restrictions on over-the-counter purchases. The law restricts over-the-counter purchases of pseudoephedrine to one product per day and 7,500 milligrams per month. Purchasers must sign a logbook accessible to law enforcement. Pharmacies dispensing schedule V pseudoephedrine products must verify the purchaser is 18 or older. The law restricts over-the-counter purchases of pseudoephedrine to one product per day and 7,500 milligrams per month. Purchasers must provide identification proving they are 18 or older and maintain a record of the purchase including purchaser's name, product details, purchase date, and pharmacist's identification. The Controlled Substances Act is amended to include penalties for registrants who violate registration conditions, such as maintaining records in various forms like hard-copy or electronic systems. The Controlled Substances Act is amended to include penalties for registrants who violate registration conditions related to the sale of pseudoephedrine products. SEC. 5. RESTRICTIONS ON PURCHASES OF PSEUDOEPHEDRINE. Amended to limit retail purchases of pseudoephedrine products without a prescription to one per day and 7,500 milligrams in a 30-day period."
}